Adalimumab for the treatment of pediatric Crohns disease

Federica Nuti, Gionata Fiorino, Silvio Danese

Research output: Contribution to journalArticlepeer-review


Inflammatory bowel diseases are characterized by a chronic relapsing course, high morbidity and impaired quality of life. Their incidence is rising, and about 25% of cases are diagnosed in pediatric age. Anti-TNF-α antibodies, such as infliximab and adalimumab (ADA), are usually administered in patients refractory to conventional therapies. However, increasing evidence suggests that they can be introduced earlier in the course of the disease, especially in patients with aggressive and extensive disease since diagnosis. ADA is a fully human anti-TNF-α antibody recently approved for pediatric Crohns disease not only in patients unresponsive to infliximab, but also as a first-line anti-TNF-α therapy. In this review, we aim to summarize the current knowledge on the use of ADA in pediatric Crohns disease and to discuss open issues regarding safety as well as future perspectives.

Original languageEnglish
Pages (from-to)963-972
Number of pages10
JournalExpert Review of Clinical Immunology
Issue number9
Publication statusPublished - Sep 2 2015


  • Adalimumab
  • anti-TNF-α antibodies
  • efficacy
  • inflammatory bowel disease
  • pediatric Crohn's disease
  • safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Adalimumab for the treatment of pediatric Crohns disease'. Together they form a unique fingerprint.

Cite this